← Leaderboards
Lashonda Y Spencer
University Of Southern California
$698,531
Attributed
$698,531
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $426.4K · FY2006–09$500K$375K$250K$125K$0
'06
'07
'08
'09
Funding mix
By agency
NIH$698,531 · 4
By mechanism
M01$698,531 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Celeste Leigh Pearce$4,768,851
- Leslie Bernstein$25,541,709
- Fred R Sattler$24,195,984
- Simon Andrew Gayther$9,015,265
- Veronica Wendy Setiawan$9,412,373
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanMonitorOrtho EvraOrtho-NovumProtease InhibitorRandomizedReproductiveResearch PersonnelResourcesSourceUnited States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseContraceptive AgentsDoseDrug KineticsEthinyl EstradiolFundingGrantHiv-1InstitutionLopinavirWeekProtocols, TreatmentContraceptives, Oral
Grant awards (4)
CLINICAL TRIAL: AACTG A5188: A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMA$49,168
M01 · FY2009 · RR · contact PI
AACTG A5188: A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMAL CONTRACEPTI$68,549
M01 · FY2008 · RR · contact PI
AACTG A5188: A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMAL CONTRACEPTI$426,361
M01 · FY2007 · RR · contact PI
AACTG A5188: A PHASE II PHARMACOKINETIC STUDY OF THE TRANSDERMAL$154,453
M01 · FY2006 · RR · contact PI